Tumor Biology

, Volume 36, Issue 4, pp 2299–2307 | Cite as

Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma

  • Hui Liu
  • Jianyu Li
  • Fengmei Wang
  • Yingtang Gao
  • Ying Luo
  • Peng Wang
  • Chenglong Li
  • Zhengyan Zhu
Research Article

Abstract

Cytokine-induced killer (CIK) cell immunotherapy exhibits significant advantages in the clinical treatment of tumors. This study was designed to compare the biological characteristics of autologous CIK cells from patients with hepatocarcinoma following different procedures for the separation of peripheral blood mononuclear cells (PBMCs). Forty-four hepatocarcinoma patients were enrolled and distributed into two groups. PBMCs were isolated either using a blood cell separator (apheresis method) or Ficoll lymphocyte separation medium (Ficoll method). The total amount, collection efficacy, and cell status of PBMCs in the two groups were determined. According to the number and status of collected PBMCs, different cultivation procedures were used for their amplification and activation and the proliferation ability, phenotype, and killing activity of CIK cells in the two groups were evaluated. Our results indicated that the number of collected PBMCs in the apheresis group was far more than that in the Ficoll group. However, the isolation rate was lower, and more cellular debris was observed in the apheresis group, which may be the cause of some untoward effects. Following in vitro culture, the enrichment time of CIK cells was longer in the Ficoll group, and the percentages of CD3+CD4+ (Th) and CD4+CD25+ (Treg) cells were higher. In the apheresis group, the percentages of CD3CD56+ (NK) and CD3+CD56+ (NKT) cells were higher, and the CIK cells exhibited a higher cytolytic activity against HepG2 hepatoma cells. In conclusion, different procedures for PBMCs separation can influence the biological activities of CIK cells, and the apheresis method is more effective at enhancing the antitumor efficacy of CIK cells. However, significant attention should be paid to the possibility of adverse reactions in apheresis donors.

Keywords

Cytokine-induced killer cell Hepatocarcinoma Peripheral blood mononuclear cells Separation modality Antitumor efficacy 

Notes

Acknowledgments

This work was supported by grants from the Tianjin Science Foundation of China (No. 13JCYBJC22500) and the Tianjin Public Health Bureau Science Foundation of China (No. 2010KY03).

Conflicts of interest

None.

References

  1. 1.
    Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol. 2014;8:71–6.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Willimsky G, Protzer U, Knolle P, Heikenwalder M. Adoptive T-cell therapy to treat liver cancer: is the liver microenvironment key? Oncotarget. 2013;4(8):1117–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, et al. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, et al. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol. 2013;9(10):1533–48.CrossRefPubMedGoogle Scholar
  5. 5.
    Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 2013;11:83.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12(6):673–84.CrossRefPubMedGoogle Scholar
  7. 7.
    Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2011;2:363–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wongkajornsilp A, Wamanuttajinda V, Kasetsinsombat K, Duangsa-ard S, Sa-ngiamsuntorn K, Hongeng S, et al. Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3+CD56+ subset through the co-culturing dendritic cells. PLoS One. 2013;8(11):e78980.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yu X, Xia W, Zhang T, Wang H, Xie Y, Yang J, et al. Enhanced cytotoxicity of IL-24 gene- modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells. Int J Hematol. 2010;92(2):276–82.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang XP, Xu M, Gao HF, Zhao JF, Xu KC. Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma. World J Gastroenterol. 2013;19(19):2956–62.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Schmidt TL, Negrin RS, Contag CH. A killer choice for cancer immunotherapy. Immunol Res. 2014;58(2–3):300–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Chien PJ, Yeh JH, Chiu HC, Hsueh YM, Chen CT, Chen MC, et al. Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis. Eur J Neurol. 2011;18(11):1350–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Li R, Wang C, Liu L, Du C, Cao S, Yu J, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012;61(11):2125–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Pan K, Wang QJ, Liu Q, Zheng HX, Li YQ, Weng DS, et al. The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer. Tumour Biol. 2014;35(1):701–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Hongeng S, Petvises S, Worapongpaiboon S, Rerkamnuaychoke B, Pakakasama S, Jootar S. Generation of CD3+CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol. 2003;77(2):175–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Tao Q, Wang H, Zhai Z. Targeting regulatory T cells in cytokine-induced killer cell cultures (Review). Biomed Rep. 2014;2(3):317–20.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Liu J, Li H, Cao S, Zhang X, Yu J, Qi J, et al. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. J Immunother. 2014;37(2):115–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Xie F, Zhang X, Li H, Zheng T, Xu F, Shen R, et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One. 2012;7(8):e42879.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zhou P, Liang P, Dong B, Yu X, Han Z, Xu Y. Phase I clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther. 2011;11(5):450–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Li XD, Xu B, Wu J, Ji M, Xu BH, Jiang JT, et al. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol. 2012;14(2):102–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang QJ, Wang H, Pan K, Li YQ, Huang LX, Chen SP, et al. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Caner. 2010;29(7):641–8.CrossRefGoogle Scholar
  22. 22.
    Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother. 2010;58(9):1325–34.CrossRefGoogle Scholar
  23. 23.
    Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol. 2004;10(8):1146–51.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011;60(10):1497–502.CrossRefPubMedGoogle Scholar
  25. 25.
    Li W, Xu LP, DI Zhao L, Wang L, Zhang Y, Gao QL, et al. Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: a case report and review of the literature. Oncol Lett. 2013;5(4):1427–9.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Yamada-Ohnishi Y, Azuma H, Urushibara N, Yamaguchi M, Fujihara M, Kobata T, et al. Cytotoxic difference of T cells expanded with anti-CD3 monoclonal antibody in the presence and absence of anti-CD 28 monoclonal antibody. Stem Cells Dev. 2004;13(3):315–22.CrossRefPubMedGoogle Scholar
  27. 27.
    Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. 2014;20(4):463–73.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Rajbhandary S, Zhao MF, Zhao N, Lu WY, Zhu HB, Xiao X, et al. Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways. Asian Pac J Cancer Prev. 2013;14(10):5825–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra43.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127–32.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Pan Y, Tao Q, Wang H, Xiong S, Zhang R, Chen T, et al. Dendritic cells decreased the concomitant expanded Tregs and Tregs related IL-35 in cytokine-induced killer cells and increased their cytotoxicity against leukemia cells. PLoS One. 2014;9(4):e93591.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wang F, Jing X, Li G, Wang T, Yang B, Zhu Z, et al. Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma. Liver Int. 2012;32(4):644–55.CrossRefPubMedGoogle Scholar
  33. 33.
    Li H, Yu JP, Cao S, Wei F, Zhang P, An XM, et al. CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol. 2007;27(3):317–26.CrossRefPubMedGoogle Scholar
  34. 34.
    Heninger AK, Theil A, Wilhelm C, Petzold C, Huebel N, Kretschmer K, et al. IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. J Immunol. 2012;189(12):5649–58.CrossRefPubMedGoogle Scholar
  35. 35.
    Shevach EM. Application of IL-2 therapy to target T regulatory cell function. Trends Immunol. 2012;33(12):626–32.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kasahara K, Sasaki N, Yamashita T, Kita T, Yodoi K, Sasaki Y, et al. CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response. J Am Heart Assoc. 2014;3(2):e000719.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Hui Liu
    • 1
  • Jianyu Li
    • 2
  • Fengmei Wang
    • 1
  • Yingtang Gao
    • 1
  • Ying Luo
    • 1
  • Peng Wang
    • 1
  • Chenglong Li
    • 1
  • Zhengyan Zhu
    • 1
  1. 1.Key Laboratory of Artificial CellTianjin Third Central HospitalTianjinChina
  2. 2.Logistics College of People’s Armed Police ForcesTianjinChina

Personalised recommendations